Janssen Pharmaceuticals (United States)

Janssen Pharmaceuticals, part of Johnson & Johnson, develops transformative medicines in oncology, immunology, neuroscience, cardiovascular, and infectious diseases. Key products include Darzalex (daratumumab) for multiple myeloma, Stelara (ustekinumab) for psoriasis and IBD, Tremfya (guselkumab) for psoriasis, Invega and Risperdal for schizophrenia, Xarelto (rivaroxaban) for blood clots, and Symtuza for HIV. Janssen’s innovative research continues delivering breakthrough treatments.